FANCL
FANCL (E3 ubiquitin-protein ligase FANCL) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
Overview
Ubiquitin ligase protein that mediates monoubiquitination of FANCD2 in the presence of UBE2T, a key step in the DNA damage pathway. Also mediates monoubiquitination of FANCI. May stimulate the ubiquitin release from UBE2W.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Olaparib. Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes genetic literature 0.83, affected pathway 0.25, literature 0.53, genetic association 0.14, animal model 0.54).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FANCL (E3 ubiquitin-protein ligase FANCL) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
- 1 · What it is
FANCL (E3 ubiquitin-protein ligase FANCL) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.
- 2 · What goes wrong in cancer
Ubiquitin ligase protein that mediates monoubiquitination of FANCD2 in the presence of UBE2T, a key step in the DNA damage pathway. Also mediates monoubiquitination of FANCI.
- 3 · How drugs use it
No product in this corpus aims at FANCL yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:20748 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NW38 (protein name, function text, keywords and locations (REST API)); CIViC gene FANCL (1 evidence items, 0 assertions, 1 variants; diseases: Castration-resistant Prostate Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000115392 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Biology
Ubiquitin ligase protein that mediates monoubiquitination of FANCD2 in the presence of UBE2T, a key step in the DNA damage pathway. Also mediates monoubiquitination of FANCI. May stimulate the ubiquitin release from UBE2W. May be required for proper primordial germ cell proliferation in the embryonic stage, whereas it is probably not needed for spermatogonial proliferation after birth. Location: Cytoplasm; Nucleus (UniProt). Locus 2p16.1 (HGNC).
- Prostate cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FANCL" OR ABSTRACT:"FANCL" OR TITLE:"FA complementation group L" OR ABSTRACT:"FA complementation group L" OR TITLE:"E3 ubiquitin-protein ligase FANCL" OR ABSTRACT:"E3 ubiquitin-protein ligase FANCL" OR TITLE:"FLJ10335" OR ABSTRACT:"FLJ10335" OR TITLE:"FAAP43" OR ABSTRACT:"FAAP43" OR TITLE:"Pog" OR ABSTRACT:"Pog") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FANCL, not a curated reading list.